[1] GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2018, 17:939-953.
[2] GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015:a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Neurol, 2017, 16:877-897.
[3] Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service[J]. Brain, 2002, 125(Pt 4):861-870.
[4] Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J. Neurofilaments as biomarkers in neurological disorders[J]. Nat Rev Neurol, 2018, 14:577-589.
[5] Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders[J]. J Neurol Neurosurg Psychiatry, 2019, 90:870-881.
[6] Thebault S, Booth RA, Freedman MS. Blood neurofilament light chain:the neurologist's troponin[J]?Biomedicines, 2020, 8:523.
[7] Didonna A, Opal P. The role of neurofilament aggregation in neurodegeneration:lessons from rare inherited neurological disorders[J]. Mol Neurodegener, 2019, 14:19.
[8] Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments and neurofilament proteins in health and disease[J]. Cold Spring Harb Perspect Biol, 2017, 9:a018309.
[9] Gafson AR, Barthélemy NR, Bomont P, Carare RO, Durham HD, Julien JP, Kuhle J, Leppert D, Nixon RA, Weller RO, Zetterberg H, Matthews PM. Neurofilaments:neurobiological foundations for biomarker applications[J]. Brain, 2020, 143:1975-1998.
[10] Yin W, Zhu Y, Yang B, Wang F, Yin K, Zhou C, Ren H, Yang X. Plasma neurofilament light chain levels are associated with depressive and anxiety symptoms in Parkinson's disease[J].Neurol Sci, 2022, 43:2839-2843.
[11] Lin WC, Lu CH, Chiu PY, Yang SY. Plasma total α-synuclein and neurofilament light chain:clinical validation for discriminating Parkinson's disease from normal control[J].Dement Geriatr Cogn Disord, 2020, 49:401-409.
[12] Barro C, Chitnis T, Weiner HL. Blood neurofilament light:a critical review of its application to neurologic disease[J]. Ann Clin Transl Neurol, 2020, 7:2508-2523.
[13] Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K; Swedish BioFINDER study. Bloodbased NfL:a biomarker for differential diagnosis of parkinsonian disorder[J]. Neurology, 2017, 88:930-937.
[14] Lin YS, Lee WJ, Wang SJ, Fuh JL. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease[J]. Sci Rep, 2018, 8:17368.
[15] van Rumund A, Marques TM, Esselink RAJ, Bloem BR, Verbeek MM. Reader response:blood NfL:a biomarker for disease severity and progression in Parkinson disease[J].Neurology, 2020, 95:657-658.
[16] Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease[J]. Mov Disord, 1998, 13:70-77.
[17] Li Q, Li Z, Han X, Shen X, Wang F, Bai L, Li Z, Zhang R, Wang Y, Zhu X. A panel of plasma biomarkers for differential diagnosis of Parkinsonian syndromes[J]. Front Neurosci, 2022, 16:805953.
[18] Bäckström DC, Eriksson Domellöf M, Linder J, Olsson B, Öhrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L.Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease[J]. JAMA Neurol, 2015, 72:1175-1182.
[19] Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ; and the NFL Group. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology:a systematic review and meta-analysis[J]. JAMA Neurol, 2019, 76:1035-1048.
[20] Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P. CSF and blood biomarkers for Parkinson's disease[J]. Lancet Neurol, 2019, 18:573-586.
[21] Hendricks R, Baker D, Brumm J, Davancaze T, Harp C, Herman A, Büdingen HV, Townsend M, Fischer SK.Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood[J]. Bioanalysis, 2019, 11:1405-1418.
[22] Lin CH, Li CH, Yang KC, Lin FJ, Wu CC, Chieh JJ, Chiu MJ.Blood NfL:a biomarker for disease severity and progression in Parkinson disease[J]. Neurology, 2019, 93:e1104-1111.
[23] Marques TM, van Rumund A, Oeckl P, Kuiperij HB, Esselink RAJ, Bloem BR, Otto M, Verbeek MM. Serum NFL discriminates Parkinson disease from atypical parkinsonisms[J]. Neurology, 2019, 92:e1479-1486.
[24] Bäckström D, Linder J, Jakobson Mo S, Riklund K, Zetterberg H, Blennow K, Forsgren L, Lenfeldt N. NfL as a biomarker for neurodegeneration and survival in Parkinson disease[J].Neurology, 2020, 95:e827-838.
[25] Ye R, Locascio JJ, Goodheart AE, Quan M, Zhang B, Gomperts SN. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease:an 8-year longitudinal study[J].Parkinsonism Relat Disord, 2021, 85:11-16.
[26] Pilotto A, Imarisio A, Conforti F, Scalvini A, Masciocchi S, Nocivelli S, Turrone R, Gipponi S, Cottini E, Borroni B, Rizzetti MC, Pizzi M, Bonanni L, Sturchio A, Espay AJ, Zetterberg H, Ashton NJ, Hye A, Padovani A. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease[J]. Parkinsonism Relat Disord, 2021, 87:41-47.
[27] Wilke C, Dos Santos MCT, Schulte C, Deuschle C, Scheller D, Verbelen M, Brockmann K, von Thaler AK, Sünkel U, Roeben B, Bujac S, Metzger FG, Maetzler W, da Costa AN, Synofzik M, Berg D. Intraindividual neurofilament dynamics in serum mark the conversion to sporadic Parkinson's disease[J]. Mov Disord, 2020, 35:1233-1238.
[28] Yuan A, Nixon RA. Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies[J].Front Neurosci, 2021, 15:689938.
[29] Brugulat-Serrat A, Salvadó G, Sudre CH, Grau-Rivera O, SuárezCalvet M, Falcon C, Sánchez-Benavides G, Gramunt N, Fauria K, Cardoso MJ, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study. Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals[J]. Brain Imaging Behav, 2020, 14:2012-2023.
[30] Arai H, Schmidt ML, Lee VM, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ. Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease[J]. Neurology, 1992, 42:1315-1322.
[31] Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease[J].JAMA Neurol, 2019, 76:791-799.
[32] Olsson B, Portelius E, Cullen NC, Sandelius Å, Zetterberg H, Andreasson U, Höglund K, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk D, McCluskey L, Elman L, Shaw LM, Toledo JB, McBride J, Hernandez-Con P, Lee VM, Trojanowski JQ, Blennow K. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders[J]. JAMA Neurol, 2019, 76:318-325.
[33] Zhu Y, Yang B, Wang F, Liu B, Li K, Yin K, Yin WF, Zhou C, Tian S, Ren H, Pang A, Yang X. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease[J]. J Neuroimmunol, 2021, 358:577662.
[34] Chen CH, Lee BC, Lin CH. Integrated plasma and neuroimaging biomarkers associated with motor and cognition severity in Parkinson's disease[J]. J Parkinsons Dis, 2020, 10:77-88.
[35] Lerche S, Wurster I, Röben B, Zimmermann M, Machetanz G, Wiethoff S, Dehnert M, Rietschel L, Riebenbauer B, Deuschle C, Stransky E, Lieplt-Scarfone I, Gasser T, Brockmann K. CSF NFL in a longitudinally assessed PD cohort:age effects and cognitive trajectories[J]. Mov Disord, 2020, 35:1138-1144.
[36] Sampedro F, Pérez-González R, Martínez-Horta S, Marín-Lahoz J, Pagonabarraga J, Kulisevsky J. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease[J]. Parkinsonism Relat Disord, 2020, 74:43-49.
[37] Chen CH, Lee BC, Lin CH. Integrated plasma and neuroimaging biomarkers associated with motor and cognition severity in Parkinson's disease[J]. J Parkinsons Dis, 2020, 10:77-88.
[38] Mangesius S, Mariotto S, Ferrari S, Pereverzyev S Jr, Lerchner H, Haider L, Gizewski ER, Wenning G, Seppi K, Reindl M, Poewe W. Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers[J].Parkinsonism Relat Disord, 2020, 77:57-63.
[39] Archer DB, Mitchell T, Burciu RG, Yang J, Nigro S, Quattrone A, Quattrone A, Jeromin A, McFarland NR, Okun MS, Vaillancourt DE. Magnetic resonance imaging and neurofilament light in the differentiation of parkinsonism[J].Mov Disord, 2020, 35:1388-1395.